United States - English - NLM (National Library of Medicine)

teva women's health, inc. - acetazolamide (unii: o3fx965v0i) (acetazolamide - unii:o3fx965v0i) - acetazolamide 500 mg - for adjunctive treatment of: chronic simple (open-angle) glaucoma, secondary glaucoma, and preoperatively in acute angleclosure glaucoma where delay of surgery is desired in order to lower intraocular pressure. diamox is also indicated for the prevention or amelioration of symptoms associated with acute mountain sickness despite gradual ascent. hypersensitivity to acetazolamide or any excipients in the formulation. since acetazolamide is a sulfonamide derivative, cross sensitivity between acetazolamide, sulfonamides and other sulfonamide derivatives is possible. acetazolamide therapy is contraindicated in situations in which sodium and/or potassium blood serum levels are depressed, in cases of marked kidney and liver disease or dysfunction, in suprarenal gland failure, and in hyperchloremic acidosis. it is contraindicated in patients with cirrhosis because of the risk of development of hepatic encephalopathy. long-term administration of diamox is contraindicated in patients with chronic non-congestive angle-c

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

mercury pharma group ltd - acetazolamide - modified-release capsule - 250mg

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - acetazolamide 250mg - tablet - 250 mg - active: acetazolamide 250mg excipient: calcium hydrogen phosphate lactose monohydrate magnesium stearate maize starch povidone sodium starch glycolate - indicated for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

New Zealand - English - Medsafe (Medicines Safety Authority)

medsurge pharma limited - acetazolamide 250mg - tablet - 250 mg - active: acetazolamide 250mg excipient: calcium hydrogen phosphate lactose monohydrate magnesium stearate maize starch povidone sodium starch glycolate - indicated for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

United States - English - NLM (National Library of Medicine)

dr. reddy's labratories inc. - estazolam (unii: 36s3eqv54c) (estazolam - unii:36s3eqv54c) - estazolam is indicated for the short-term management of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings. both outpatient studies and a sleep laboratory study have shown that estazolam administered at bedtime improved sleep induction and sleep maintenance (see clinical pharmacology ). because insomnia is often transient and intermittent, the prolonged administration of estazolam is generally neither necessary nor recommended. since insomnia may be a symptom of several other disorders, the possibility that the complaint may be related to a condition for which there is a more specific treatment should be considered. there is evidence to support the ability of estazolam to enhance the duration and quality of sleep for intervals up to 12 weeks (see clinical pharmacology ). estazolam is contraindicated with ketoconazole and itraconazole, since these medications significantly impair oxidative metabolism mediated by cyp3a (see warnings and precautions, drug interactions ). estazolam is a controlled substance in schedule iv. estazolam is a benzodiazepine and a cns depressant with a potential for abuse and addiction. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed. drug addiction is a cluster of behavioral, cognitive, and physiological phenomena that may include a strong desire to take the drug, difficulties in controlling drug use (e.g., continuing drug use despite harmful consequences, giving a higher priority to drug use than other activities and obligations), and possible tolerance or physical dependence. even taking benzodiazepines as prescribed may put patients at risk for abuse and misuse of their medication. abuse and misuse may lead to addiction. abuse and misuse of benzodiazepines often (but not always) involve the use of doses greater than the maximum recommended dosage and commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes, including respiratory depression, overdose, or death. benzodiazepines are often sought by individuals who abuse drugs and other substances, and by individuals with addictive disorders (see warnings, abuse, misuse, and addiction ). the following adverse reactions have occurred with benzodiazepine abuse and/or misuse: abdominal pain, amnesia, anorexia, anxiety, aggression, ataxia, blurred vision, confusion, depression, disinhibition, disorientation, dizziness, euphoria, impaired concentration and memory, indigestion, irritability, muscle pain, slurred speech, tremors, and vertigo. the following severe adverse reactions have occurred with benzodiazepine abuse and/or misuse: delirium, paranoia, suicidal ideation and behavior, seizures, coma, breathing difficulty, and death. death is more often associated with polysubstance use (especially benzodiazepines with other cns depressants such as opioids and alcohol). estazolam may produce physical dependence from continued therapy. physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug. abrupt discontinuation or rapid dosage reduction of benzodiazepines or administration of flumazenil, a benzodiazepine antagonist, may precipitate acute withdrawal reactions, including seizures, which can be life-threatening. patients at an increased risk of withdrawal adverse reactions after benzodiazepine discontinuation or rapid dosage reduction include those who take higher dosages (i.e., higher and/or more frequent doses) and those who have had longer durations of use (see warnings, dependence and withdrawal reactions ). to reduce the risk of withdrawal reactions, use a gradual taper to discontinue estazolam or reduce the dosage (see dosage and administration, discontinuation or dosage reduction of estazolam and warnings, dependence and withdrawal reactions ). acute withdrawal signs and symptoms associated with benzodiazepines have included abnormal involuntary movements, anxiety, blurred vision, depersonalization, depression, derealization, dizziness, fatigue, gastrointestinal adverse reactions (e.g., nausea, vomiting, diarrhea, weight loss, decreased appetite), headache, hyperacusis, hypertension, irritability, insomnia, memory impairment, muscle pain and stiffness, panic attacks, photophobia, restlessness, tachycardia, and tremor. more severe acute withdrawal signs and symptoms, including life-threatening reactions, have included catatonia, convulsions, delirium tremens, depression, hallucinations, mania, psychosis, seizures, and suicidality. protracted withdrawal syndrome associated with benzodiazepines is characterized by anxiety, cognitive impairment, depression, insomnia, formication, motor symptoms (e.g., weakness, tremor, muscle twitches), paresthesia, and tinnitus that persists beyond 4 to 6 weeks after initial benzodiazepine withdrawal. protracted withdrawal symptoms may last weeks to more than 12 months. as a result, there maybe difficulty in differentiating withdrawal symptoms from potential re-emergence or continuation of symptoms for which the benzodiazepine was being used. tolerance to estazolam may develop from continued therapy. tolerance is a physiological state characterized by a reduced response to a drug after repeated administration (i.e., a higher dose of a drug is required to produce the same effect that was once obtained at a lower dose). tolerance to the therapeutic effect of estazolam may develop estazolam; however, little tolerance develops to the amnestic reactions and other cognitive impairments caused by benzodiazepines.

Canada - English - Health Canada

valeant canada lp / valeant canada s.e.c. - acetazolamide - tablet - 250mg - acetazolamide 250mg - carbonic anhydrase inhibitors

Israel - English - Ministry of Health

taro pharmaceutical industries ltd - acetazolamide - tablets - acetazolamide 250 mg - acetazolamide - acetazolamide - for adjunctive treatment of drug induced edema and edema due to congestive heart failure. chronic simple (open angle) glaucoma, secondary glaucoma and pre operatively in acute angle closure glaucoma where delay of surgery is desired in order to lower intraocular pressure. acute mountain sickness.

Australia - English - Department of Health (Therapeutic Goods Administration)

phebra pty ltd - acetazolamide sodium, quantity: 549.5 mg (equivalent: acetazolamide, qty 500 mg) - injection, powder for - excipient ingredients: sodium hydroxide; hydrochloric acid - for adjunctive treatment of: oedema due to congestive heart failure; drug induced oedema; centrencephalic epilepsies (petit mal, unlocalised seizures); chronic simple (open-angle) glaucoma, secondary glaucoma and preoperatively in acute angle-closure glaucoma where delay of surgery is desired in order to lower intraocular pressure.

Malta - English - Medicines Authority

remedica limited limassol industrial estate, aharnon street, 3056 limassol, cyprus - acetazolamide - tablet - acetazolamide 250 mg - ophthalmologicals

Canada - English - Health Canada

sterimax inc - acetazolamide (acetazolamide sodium) - powder for solution - 500mg - acetazolamide (acetazolamide sodium) 500mg - antiglaucoma agents